RENODAPT- S 360 Contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency glucose-galactose malabsorption should not take this medicine. The concomitant administration of MPA and drugs which interfere with enterohepatic circulation, for example cholestyramine activated charcoal, may result in sub therapautic systemic MPA exposure and reduced efficacy.
RENODAPT- S 360 Each enteric coated tablet contains: Mycophenolic acid 360 mg (as sodium salt)
Colours: Tartrazine Yellow, Iron Oxide Yellow and Titanium Dioxide IP.